Evotec SE · ISIN: DE0005664809 · EQS - Company News

Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV

JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV  AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV Hamburg, Germany, 07 February 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its Seattle-based subsidiary Just – Evotec Biologics, Inc. has expanded its relationship with Advanced BioScience L...

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Evotec SE

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
07 February 2024 07:30AM
Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV
JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV  AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV Hamburg, Germany, 07 February 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809;...
Evotec SE
22 January 2024 07:30AM
Invitation to Conference Call
Hamburg, Germany, 22 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec’s Supervisory Board, Prof. Iris Löw-Friedrich and Evotec’s CEO Dr Mari...
Evotec SE
10 January 2024 03:30PM
Evotec and Crohn´s & Colitis Foundation enter agreement to advance drug discovery for novel IBD therapies
EVOTEC JOINS FORCES WITH THE CROHN’S & COLITIS FOUNDATION’S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE (“IBD”) THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR TWO INNOVATIVE DRUG TARGETS ADDRESSING FIBROSIS AND IMPAIR...
Evotec SE
08 January 2024 07:30AM
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH   Hamburg, Germany, 08 January 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership with Bristol Myer...
Evotec SE
04 January 2024 07:30AM
Evotec and Owkin enter an A.I.-powered strategic partnership to accelerate therapeutics pipeline in oncology and I&I
PARTNERSHIP COMBINES OWKIN’S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN’S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYMENTS TO EVOTEC  Hamburg, Germany, and Paris, France, 04 Janu...
Evotec SE
03 January 2024 06:25PM
Evotec announces CEO transition
DR WERNER LANTHALER TO STEP DOWN AS CEO REMAINS AVAILABLE AS STRATEGIC ADVISOR TO THE SUPERVISORY BOARD TO FACILITATE A SMOOTH TRANSITION DR MARIO POLYWKA HAS AGREED TO STEP IN AS INTERIM CEO SEARCH STARTED FOR PERMANENT CEO TO CONTINUE BUILDING THE GLOBALLY LEADING COMPANY FOR EXTERNAL INNOVATION EVOTEC CONFIRMS GUIDANCE 2023 Hamburg, Germany...
Evotec SE
03 January 2024 06:24PM
Evotec announces CEO transition
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to serve until the end of his current term, for personal reasons. The Supervisory Bo...
Evotec SE
19 December 2023 07:30AM
Evotec receives US$ 2.5 m grant to leverage human iPSC-derived teratogenicity platform for global health programmes
EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY (“GHDC”) AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC’S IPSC-DERIVED HIGH-THROUGHPUT TERATOGENICITY PLATFORM   Hamburg, Germany, 19...
Evotec SE
14 December 2023 07:30AM
Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases
GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF ANCA-ASSOCIATED VASCULITIS CHARITÉ – UNIVERSITÄTSMEDIZIN BERLIN WILL COLLECT BIOSAMPLES FROM ANCA-ASSOCIATED VASCULITIS PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE...
Evotec SE
06 December 2023 07:30AM
Evotec-partner Jingxin receives approval for EVT201 in China
EVT201 APPROVED BY THE CHINESE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (“NMPA”) AS A NOVEL SHORT-TERM TREATMENT OF INSOMNIA EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA   Hamburg, Germany, 06 December 2023: Evotec SE (Frankfurt Stock Exc...
Evotec SE
15 November 2023 07:30AM
Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
PRECISION MEDICINE CAPABILITIES SHAPING (NEW) MARKETS WITH FIRST-IN-CLASS THERAPEUTICS PANOMICS, IPSC & A.I./M.L. PLATFORMS ARE THE STEP CHANGE FOR GROWTH AND ACCELERATED PIPELINE BUILDING CONFIRMATION OF ACTION PLAN 2025 GOALS AND PROGRESS UPDATE Hamburg, Germany, 15 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN...
Evotec SE
08 November 2023 07:00AM
Evotec SE reports results for the first nine months 2023 and provides corporate update
CONTINUATION OF STRONG GROWTH IN DEMANDING MARKETS PARADIGM-SHIFTING OFFERINGS ARE STRONGEST GROWTH DRIVERS PIPELINE PROGRESS, E.G. WITH ADVANCED ASSET IN NEURODEGENERATION ALL ELEMENTS OF GUIDANCE CONFIRMED   Hamburg, Germany, 08 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announc...
Evotec SE
07 November 2023 07:30AM
Evotec and Dewpoint Therapeutics enter strategic partnership in oncology
STRATEGIC PARTNERSHIP TO ACCELERATE DEWPOINT’S LEADING ONCOLOGY PIPELINE PROGRAMMES TO INVESTIGATIONAL NEW DRUG APPLICATIONS COLLABORATION LEVERAGES EVOTEC’S FULLY INTEGRATED, CLINICAL-ENABLING INDIGO CAPABILITY PLATFORM AGREEMENT IS BASED ON A RISK-SHARING ARRANGEMENT FOLLOWED BY MILESTONE AND ROYALTY PAYMENTS TO EVOTEC BASED ON SUCCESS OF OVER...
Evotec SE
01 November 2023 12:05PM
Evotec SE to announce results for the first nine months 2023 on 08 November 2023
Hamburg, Germany, 01 November 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first nine months 2023 on Wednesday, 08 November 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conf...
Evotec SE
05 October 2023 07:30AM
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
  A UNIQUE COMPANY CREATION VEHICLE INITIATED BY LIGHTSTONE VENTURES AND EVOTEC SE, AND ESTABLISHED WITH PARTNERS CLAVYSTBIO, LEAPS BY BAYER, POLARIS PARTNERS, AND THE POLARIS INNOVATION FUND FIRST-OF-ITS-KIND PARTNERSHIP IN SINGAPORE AND ASIA LEVERAGES BREAKTHROUGH SCIENCE FROM RESEARCHERS AT AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (“A*STAR”...
Evotec SE
27 September 2023 07:30AM
Launch of partnering agreement to strengthen biotech innovators in shared R&D economy
  LABCENTRAL, BIOLABS, MBC BIOLABS PARTNER WITH EVOTEC TO SUPPORT BIOTECH INNOVATORS THROUGH CRITICAL INFLECTION POINTS AGREEMENT LEVERAGES EVOTEC’S INTEGRATED END-TO-END SHARED R&D PLATFORM TO ENABLE GREATER ACCESS TO INDUSTRY-GRADE CAPABILITIES AND DRUG HUNTING EXPERTISE FOR LIFE SCIENCES AND BIOTECH STARTUPS ACROSS THE GLOBAL LABCENTRAL / ...
Evotec SE
26 September 2023 01:35PM
Evotec and Novo Nordisk launch LAB eN² to accelerate translation in cardiometabolic diseases
LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTER FOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC IDEAS TO THERAPEUTIC PRODUCT CANDIDATES IN THE CARDIOMETABOLIC SPACE   Hamburg, Germany, and Cambridge, Mass., USA, 26 September 2023: Evotec SE (Fr...
Evotec SE
29 August 2023 07:00AM
Evotec SE reports results for the first half-year 2023 and provides corporate updates
  NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED Hamburg, Germany, 29 August 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced its financial results and corporate updates for the first half-year of 2023.HIGHLIGHTS Q2 CYBER-INCIDENT...
Evotec SE
22 August 2023 02:00PM
Evotec SE reports first half-year 2023 results on 29 August 2023
Hamburg, Germany, 22 August 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2023 on Tuesday, 29 August 2023. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conferenc...
Evotec SE
27 July 2023 08:15PM
Evotec provides update on financial impact of cyber-attack
Hamburg, Germany, 27 July 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 ...
Evotec SE
27 July 2023 08:15PM
Evotec provides update on financial impact of cyber-attack
Hamburg, Germany, 27 July 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that it is adjusting its guidance for the fiscal year 2023 due to the impact of the cyber-attack. For the current fiscal year, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 ...
Evotec SE
27 July 2023 07:49PM
Evotec provides update on financial impact of cyber-attack
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023. Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpa...
Evotec SE
27 July 2023 07:49PM
Evotec provides update on financial impact of cyber-attack
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it is adjusting its guidance for the fiscal year 2023. Due to the impact of the cyber-attack, the company now expects Group revenues in the range of € 750 – 790 m (previously € 820 – 840 m); unpa...
Evotec SE
11 July 2023 07:30AM
Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
  EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALT...
Evotec SE
11 July 2023 07:30AM
Evotec and Bristol Myers Squibb enter licence agreement within neuroscience partnership
  EVOTEC AND BRISTOL MYERS SQUIBB ENTER EXCLUSIVE GLOBAL LICENCE AGREEMENT FOR SELECTED PROGRAMMES DEVELOPED AND PROGRESSED IN THE COLLABORATION SELECTED PROGRAMMES FURTHER STRENGTHEN THE PROGRAMME PIPELINE OF NEURODEGENERATION ASSETS EVOTEC RECEIVES $ 40 M PAYMENT AND IS ELIGIBLE TO EARN PERFORMANCE MILESTONE PAYMENTS, AS WELL AS TIERED ROYALT...
Evotec SE
05 July 2023 07:30AM
Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
  JUST – EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE NOVO ANTIBODY DESIGN OF THERAPEUTIC CANDIDATES EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES Hamburg, Germany...
Evotec SE
05 July 2023 07:30AM
Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
  JUST – EVOTEC BIOLOGICS WILL SUPPORT THE DOD WITH RAPID, COST-EFFICIENT DEVELOPMENT OF SAFE, EFFICACIOUS MABS TARGETING ORTHOPOXVIRUSES PROJECT INCLUDES EXISTING ANTIBODY DEVELOPMENT, ANTIBODY DISCOVERY, AND AI-DRIVEN DE NOVO ANTIBODY DESIGN OF THERAPEUTIC CANDIDATES EVOTEC WILL PROVIDE PRE-CLINICAL AND CLINICAL TRIAL SERVICES Hamburg, Germany...
Evotec SE
29 June 2023 07:30AM
Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC   Hamburg, Germany, 29 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that it is to receive a €...
Evotec SE
29 June 2023 07:30AM
Evotec receives milestone payment for first patient dosed in Phase I study of Bayer kidney disease programme
PHASE I CLINICAL TRIAL INITIATED TO EVALUATE SEMA3A MAB AS POTENTIAL TREATMENT FOR ALPORT SYNDROME FIRST DOSING OF FIRST STUDY PARTICIPANT TRIGGERS MILESTONE PAYMENT OF € 2 M TO EVOTEC   Hamburg, Germany, 29 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that it is to receive a €...
Evotec SE
20 June 2023 04:55PM
Evotec SE Annual General Meeting 2023 approves all proposed agenda items
  ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY REPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023 Hamburg, Germany, 20 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s vi...
Evotec SE
20 June 2023 04:55PM
Evotec SE Annual General Meeting 2023 approves all proposed agenda items
  ALL AGENDA ITEMS ADOPTED WITH THE REQUIRED MAJORITY REPORT OF FIRST HALF-YEAR 2023 RESULTS ON 29 AUGUST 2023 Hamburg, Germany, 20 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s vi...
Evotec SE
05 June 2023 07:30AM
Evotec presents sustainability strategy
  TOGETHER FOR A SUSTAINABLE AND EFFICIENT SHARED R&D ECONOMY PRECISION MEDICINES AND BETTER ACCESS TO BIOTHERAPEUTICS ESG PERFORMANCE REPORT HIGHLIGHTS SUSTAINABILITY AS A COMPETITIVE ADVANTAGE IN CHALLENGING TIMES   Hamburg, Germany, 05 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today presents a...
Evotec SE
05 June 2023 07:30AM
Evotec presents sustainability strategy
  TOGETHER FOR A SUSTAINABLE AND EFFICIENT SHARED R&D ECONOMY PRECISION MEDICINES AND BETTER ACCESS TO BIOTHERAPEUTICS ESG PERFORMANCE REPORT HIGHLIGHTS SUSTAINABILITY AS A COMPETITIVE ADVANTAGE IN CHALLENGING TIMES   Hamburg, Germany, 05 June 2023: Evotec SE (Frankfurt Stock Exchange: EVT, ISIN: DE0005664809; NASDAQ: EVO) today presents a...
Evotec SE
02 June 2023 07:30AM
Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM HENIPAVIRAL AGENTS ARE PRIORITY PATHOGENS LISTED ON THE WHO’S R&D BLUEPRINT LIST OF EPIDEMIC THREATS NEEDING URGENT R&D ACTION   Hamburg,...
Evotec SE
02 June 2023 07:30AM
Evotec receives grant from Open Philanthropy for discovery of RNA-targeting Henipavirus therapeutics
$ 1.7 M-GRANT FROM OPEN PHILANTHROPY WILL SUPPORT DEVELOPMENT OF SMALL MOLECULE ANTIVIRALS THAT TARGET VIRAL RNA IN HENIPAVIRUSES EVOTEC LEVERAGES ITS PROPRIETARY SMALL MOLECULE RNA TARGETING PLATFORM HENIPAVIRAL AGENTS ARE PRIORITY PATHOGENS LISTED ON THE WHO’S R&D BLUEPRINT LIST OF EPIDEMIC THREATS NEEDING URGENT R&D ACTION   Hamburg,...
Evotec SE
12 May 2023 11:55PM
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE” QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED   Hamburg, Germany, 12 May 2023: Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809; NASDAQ: EVO) today published its Annual Report for the fiscal ...
Evotec SE
12 May 2023 11:55PM
Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023
PUBLICATION OF ANNUAL REPORT 2022: “AHEAD OF THE CURVE” QUALITATIVE QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2023 GUIDANCE FOR FY2023 AND MID-TERM GUIDANCE FOR 2025 UNCHANGED   Hamburg, Germany, 12 May 2023: Evotec SE (Frankfurt Stock Exchange: Prime Standard, ISIN: DE0005664809; NASDAQ: EVO) today published its Annual Report for the fiscal ...
Evotec SE
09 May 2023 08:07PM
Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
JUST – EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST – EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXE...
Evotec SE
09 May 2023 08:07PM
Just – Evotec Biologics launches tech partnership for biosimilars development and commercial manufacturing
JUST – EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULES JUST – EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXE...
Evotec SE
09 May 2023 08:05PM
Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimi...
Evotec SE
09 May 2023 08:05PM
Just – Evotec Biologics enters strategic biosimilars partnership with Sandoz
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that Evotec’s Seattle-based subsidiary, Just – Evotec Biologics, Inc., has entered a multi-year, long-term tech partnership with Sandoz for the immediate development and subsequent manufacturing of multiple biosimi...
Evotec SE
10 April 2023 02:00PM
Evotec SE provides update on cyber attack
Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts   Hamburg, Germany, 10 April 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual ac...
Evotec SE
10 April 2023 02:00PM
Evotec SE provides update on cyber attack
Business continuity upheld at all global sites after cyber attack Forensic examination ongoing with external experts   Hamburg, Germany, 10 April 2023: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced an update on the cyber attack that was detected on 06 April, 2023. Evotec noticed unusual ac...
Evotec SE
07 April 2023 03:10PM
Cyber Attack on Evotec
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnected from the Internet to secure from data corruption or breaches. The IT systems ...
Evotec SE
07 April 2023 03:10PM
Cyber Attack on Evotec
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that on 06 April, 2023 a cyber attack occurred on Evotec‘s IT systems. As a result, the systems were shut down proactively and disconnected from the Internet to secure from data corruption or breaches. The IT systems ...
Evotec SE
28 March 2023 11:02AM
Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC’S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALES   Hamburg, Germany, 28 March 2023: Evotec SE (Fra...
Evotec SE
28 March 2023 11:02AM
Evotec and Bristol Myers Squibb extend and expand strategic neurodegeneration partnership
8-YEAR EXTENSION AND EXPANSION OF ONGOING COLLABORATION TO DEVELOP A BROADENED PROGRAMME PIPELINE IN NEURODEGENERATIVE DISEASES PARTNERSHIP LEVERAGES EVOTEC’S PRECISION MEDICINE PLATFORMS FINANICAL TERMS INCLUDE $ 50 M UPFRONT PAYMENT, PERFORMANCE MILESTONES AND TIERED ROYALTIES ON PRODUCT SALES   Hamburg, Germany, 28 March 2023: Evotec SE (Fra...
Evotec SE
28 March 2023 11:01AM
Evotec and Bristol Myers Squibb expand strategic neurodegeneration partnership
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its strategic partnership with Bristol Myers Squibb (NYSE:BMY) in neurodegeneration, originally signed in 2016. Aim of the 8-year extension of the strategic alliance is ...
Evotec SE
More Evotec SE related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 33 15th February 2024 Dohrmann, Dr. Cord DD
Short Seller (DE) 31 26th February 2024 AHL Partners LLP SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN